The genomics market is easy to lump together and easy to misunderstand, because it is really three different businesses wearing one name. Reading DNA, writing DNA, and editing DNA are distinct tasks with distinct economics, and the stocks in each layer behave very differently. This survey maps the basket, names the leaders, and shows where the “Imperium” pitch’s picks sit inside it.
The Three Layers of the Genomics Basket
The cleanest way to sort genomics stocks is by the job they do. The read layer sequences DNA, decoding what is already there. The write layer synthesizes DNA, building new sequences from scratch. The edit layer, the CRISPR names, rewrites existing DNA inside a living cell. The Imperium pitch lives almost entirely in the write layer, with a foot in the software and apps layers above it.
Understanding that split matters more than any single stock, because the three layers are at different stages of maturity. Reading is a mature, commodity-like business. Writing is the fast-growing middle. Editing is the earliest and most speculative. An investor who treats all three the same is making a category error before they have picked a single name.
The Read Layer: Illumina, Pacific Biosciences, and 10x Genomics
The read layer is where the cost collapse happened first. Illumina (ILMN) dominates short-read sequencing, the workhorse of clinical and research genomics, with the scale and installed base of an incumbent. Pacific Biosciences (PACB) leads in long reads, the approach that handles the difficult, repetitive regions short reads miss. 10x Genomics (TXG) leads in single-cell profiling, reading individual cells rather than bulk samples.
These three are complements, not a winner-take-all fight, and a well-equipped lab often runs all of them. The catch is that the read layer no longer commands the premium pricing it once did, because the cost of reading a genome has fallen so far. The read layer is real and essential, but it is the mature half of the basket.
The Write Layer: Twist Bioscience and Codexis
The write layer is where the pitch’s anchor sits. Twist Bioscience (TWST) is the silicon-layer pick, synthesizing DNA on silicon chips through its NanoWell technology, with fifteen consecutive quarters of roughly 20% revenue growth and a partner list that includes Amazon, Microsoft, and Illumina. Codexis (CDXS) is the other write-layer name, a company that engineers enzymes to run industrial chemical processes, and it is the least discussed name in the layer.
The write layer is the bottleneck that decides the pace of the whole field, and it is where the pitch argues the money will be made. That is also where the valuation risk concentrates: Twist trades at a premium that has drawn a Sell rating and a $45 target from BWS Financial, so the technology and the stock price are two separate questions. Our Twist Bioscience stock piece sorts the financials from the story.
The Software and Apps Layers: Ginkgo and Absci
Above the write layer sit the software and applications. Ginkgo Bioworks is the pitch’s software layer, the “Microsoft” of the DNA revolution, and it has pivoted from custom molecules to selling autonomous lab equipment for AI and pharma companies, with a first sale to Novo Nordisk and new government wins with ARPA-H and the NSF. Absci is the apps layer, with a baldness drug called ABS-201 and a stake from Eli Lilly, and its proof-of-concept data is due in December with full results in early 2027. We cover Ginkgo’s turnaround and its risks in our Ginkgo Bioworks stock piece.
These are the highest-variance names in the basket. Ginkgo’s collapse from a roughly $20 billion SPAC-era peak to around $539 million is a reminder of how far these stories can swing, and Absci’s fate rides on a single clinical readout.
How to Think About the Basket
The honest frame for the whole basket is simple. The theme is real and well funded, with names like Illumina, Thermo Fisher, and Danaher competing at the equipment layer and buyers like Amazon, Eli Lilly, and Anthropic putting real money into the space. But these are high-volatility biotech names, not a diversified index, and several of them have already round-tripped once.
The edit layer, which sits alongside rather than inside the pitch, is a separate animal worth its own look. For that, our gene editing stocks piece covers the CRISPR names and how editing differs from synthesis. The practical rule is to buy the layer you understand, at a price you can defend, and to hold the pitch’s headline numbers at arm’s length.
A Note on Volatility
If there is one number that captures the risk in this basket, it is the distance some of these names have already traveled. Ginkgo Bioworks went from a roughly $20 billion peak to around $539 million, and the read-layer leaders have spent years in their own drawdowns. These are high-variance stocks, and a basket of them is not a substitute for a diversified holding. Position sizing, not thesis strength, is what keeps a genomics allocation from doing damage to a portfolio. The theme is worth owning; the volatility is worth respecting.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.